Sanofi has presented long-term maintenance data from the Phase IIb RELIEF UC-CD study of its TL1A-targeting monoclonal antibody (mAb), duvakitug, for ulcerative colitis (UC) and Crohn's disease (CD). Duvakitug, in-licensed by Sanofi in 2023, is designed to block the TL1A cytokine, which plays a role in immune dysregulation in autoimmune conditions. The 44-week maintenance data showed that 47% and 58% of UC patients treated with the 450mg and 900mg doses, respectively, achieved clinical remission. In the CD cohort, 41% and 55% of patients achieved endoscopic remission with the same doses.
The safety profile of duvakitug was consistent with earlier data, with the most common adverse events being upper respiratory tract infections, nasopharyngitis, CD and hypertension. These long-term results follow positive 12-week induction data previously reported.

According to PharmCube's NextBiopharm® database, Sanofi is also developing duvakitug in asthma and irritable bowel syndrome. Click here to request a free trial for NextBiopharm®.